NVO

Stock Details

NVO is Novo Nordisk A/S's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 141.56$. Average daily volumn in 3 months 1.44M. Market cap 348.72B

Stock symbol : NVO. Exchange : NYSE. Currency : USD
Lastest price : 155.00$. Total volume : 566.68k. Market state REGULAR
Click reload if you want to check the lastest price on market!!!

Novo Nordisk A/S (NVO)

Last Price

155.00$

Change

0.30

Volume

566.68k


Previous Close	154.70
Open	155.66
Day Range	154.53-155.86
Bid	0.00 x 800
Ask	0.00 x 800
Volume	566.68k
Average Volume	1.44M


Market Cap	348.72B
Beta	0.31
52 Week Range	95.02-155.86
Trailing P/E	43.91
Foward P/E	29.92
Dividend (Yield %)	1.14%
Ex-Dividend Date	2023-03-24

Financial Details

According to Novo Nordisk A/S's financial reports the company's revenue in 2022 were 176.95B an increase( +25.71%) over the years 2021 revenue that were of 140.8B. In 2022 the company's total earnings were 55.52B while total earnings in 2021 were 47.76B( +17.02%).

Loading ...

Organization

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormon... e replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Market Cap:

348.72B

Revenue:

176.95B

Total Assets:

241.26B

Total Cash:

12.65B

News about "Novo Nordisk A/S"

Novo Nordisk A/S - share repurchase programme

Source from : Yahoo! Sports - 1 days ago

On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the ...See details»

Novo Nordisk A/S (NVO) Stock: A Closer Look at the Analyst Ratings

Source from : newsheater - 14 days ago

Novo Nordisk A/S (NYSE: NVO) has a price-to-earnings ratio of 41.33x that is above its average ratio. Additionally, the 36-month beta value for NVO is 0.47. There are mixed opinions on the stock, with ...See details»

Novo Nordisk (NVO) Meets Semaglutide Higher Dosage Study Goal

Source from : Zacks.com on MSN - 1 days ago

Novo Nordisk A/S NVO announced positive top-line results from its phase IIIb PIONEER PLUS study. The study evaluates the safety and efficacy of its once-daily oral semaglutide 25 mg and 50 mg versus ...See details»

Novo Nordisk A/S (NVO) Shares Down Despite Recent Market Volatility

Source from : newsheater - 5 days ago

Novo Nordisk A/S (NYSE: NVO)’s stock price has decreased by -0.41 compared to its previous closing price of 147.29. Nevertheless, the company has seen a gain of 4.05% in its stock price over the last ...See details»

Novo Nordisk A/S Series B

Source from : Wall Street Journal - 15 days ago

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»

Novo Nordisk A/S: Trading In Novo Nordisk Shares By Board Members, Executives And Associated Persons

Source from : Mena FN - 1 month ago

Bagsværd, Denmark, 10 February 2023 - This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their ...See details»

Novo Nordisk A S (NVO)

Source from : Insider Monkey - 1 month ago

Operator: Good day, and thank you for standing by. Welcome to the Q4 2022 Novo Nordisk A/S Earnings Conference Call. At this time, all participants are in a listen-only mode. Mawer Investment ...See details»

Novo Nordisk A/S: Novo Nordisk to expand R&D presence in greater Boston area

Source from : Finanznachrichten - 26 days ago

This new hub, which will leverage the company's existing presence in Lexington, Cambridge and Watertown, Massachusetts, will be home to the majority of Novo Nordisk's US-based research and ...See details»

Novo Nordisk (NVO) Receives a Buy from Bank of America Securities

Source from : Business Insider - 3 days ago

Bank of America Securities analyst Sachin Jain maintained a Buy rating on Novo Nordisk (NVO – Research Report) yesterday and set a price target of $174.00. The company’s shares closed ...See details»

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Source from : Yahoo! Sports - 5 days ago

Bagsværd, Denmark, 23 March 2023 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, Chair of the Board of Directors communicated: “We are very ...See details»

Obesity Drug Hit Makes Novo Nordisk More Valuable Than Nestle

Source from : YAHOO!News - 4 days ago

It’s the Wegovy effect. Most Read from BloombergJack Dorsey’s Block Vows to Fight Back After Hindenburg Says It’s Short the StockUBS Sends Khan to Stem Credit Suisse’s Private Banker ExitsCredit ...See details»

Novo Nordisk to slash US insulin prices, following move by Eli Lilly

Source from : Yahoo News - 14 days ago

(Reuters) - Novo Nordisk said on Tuesday it would cut U.S. list prices for several insulin products by up to 75% next year, joining rival Eli Lilly and Co as political pressure mounts to make these ...See details»

Novo Nordisk A/S - share repurchase programme

Source from : Yahoo Finance - 15 days ago

Bagsværd, Denmark, 13 March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and ...See details»